aminosalicylic acid has been researched along with Tuberculosis, Drug-Resistant in 56 studies
Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.
4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 7.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| "Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism were reported." | 7.71 | [Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism]. ( Horiba, M; Kimura, T; Mizutani, H; Shindoh, J; Son, M; Wakahara, K, 2001) |
| " A PAS population pharmacokinetic model in two dosing regimens was developed; potential covariates affecting its pharmacokinetics were examined, and Monte Carlo simulations were conducted evaluating the pharmacokinetic-pharmacodynamic index." | 6.79 | Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. ( de Kock, L; Derendorf, H; Diacon, AH; Donald, PR; Hernandez, KR; Prescott, K; Rosenkranz, B; Sy, SK; Yu, M, 2014) |
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 3.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| " Hypothyroidism is a common AE associated with ethionamide, p-aminosalicylic acid (PAS), and stavudine." | 3.79 | High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India. ( Andries, A; Dalal, A; Das, M; Desai, C; Fernandes, D; Isaakidis, P; Khan, S; Mansoor, H; Migliori, GB; Paryani, R; Saranchuk, P; Sotgiu, G; Verma, R, 2013) |
| "Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism were reported." | 3.71 | [Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism]. ( Horiba, M; Kimura, T; Mizutani, H; Shindoh, J; Son, M; Wakahara, K, 2001) |
| " A PAS population pharmacokinetic model in two dosing regimens was developed; potential covariates affecting its pharmacokinetics were examined, and Monte Carlo simulations were conducted evaluating the pharmacokinetic-pharmacodynamic index." | 2.79 | Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. ( de Kock, L; Derendorf, H; Diacon, AH; Donald, PR; Hernandez, KR; Prescott, K; Rosenkranz, B; Sy, SK; Yu, M, 2014) |
| "After the completion of the treatment course, the negative sputum conversion rate in V+D+M treatment protocol group was 84%, significantly higher than that in the control group (42%); the former group showed a focal absorption rate and pulmonary cavity closure rate of 83% and 66%, which were 33% and 26% respectively in the latter." | 2.71 | [Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis]. ( Li, SM; Xing, BC; Zheng, XM, 2004) |
| " These drugs are associated with numerous adverse events that can cause severe morbidity, such as deafness, and in some instances can lead to death." | 2.66 | Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. ( Ahmad, N; Baghaei, P; Barkane, L; Benedetti, A; Brode, SK; Brust, JCM; Campbell, JR; Chang, VWL; Falzon, D; Guglielmetti, L; Isaakidis, P; Kempker, RR; Kipiani, M; Kuksa, L; Lan, Z; Lange, C; Laniado-Laborín, R; Menzies, D; Nahid, P; Rodrigues, D; Singla, R; Udwadia, ZF, 2020) |
| " The current PASER dosing regimen is based on recommendations derived from older studies using a variety of different PAS formulations and relegate PAS to a role as an exclusively bacteriostatic agent." | 2.66 | The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance. ( Abulfathi, AA; Adams, K; Diacon, AH; Donald, PR; Reuter, H; Svensson, EM, 2020) |
| " It is important to generate pharmacokinetic studies of drugs used to treat MDR TB in children in different settings, which would provide useful information on the adequacy of drug doses." | 2.61 | Pharmacokinetics of Second-Line Anti-Tubercular Drugs. ( Ramachandran, G, 2019) |
| "Ethionamide and PAS were the most frequently reported drugs that associated with the occurrence of hypothyroidism." | 2.61 | Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis. ( Holakouie-Naieni, K; Lejisa, T; Mansournia, MA; Mola, M; Tesfaye, E; Tola, HH; Yaseri, M, 2019) |
| " para-Aminosalicylic acid (PAS), an important second-line agent for treating drug-resistant Mycobacterium tuberculosis, has moderate bioavailability and rapid clearance that necessitate high daily doses of up to 12 g per day, which in turn causes severe gastrointestinal disturbances presumably by disruption of gut microbiota and host epithelial cells." | 1.72 | Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS). ( Aldrich, CC; Baughn, AD; Boshoff, HIM; Dartois, V; Hegde, PV; Howe, MD; Jia, Z; Pan, Y; Remache, B; Sharma, S; Zimmerman, MD, 2022) |
| " A population pharmacokinetic model was developed describing PAS pharmacokinetics in children receiving routine RR-TB treatment." | 1.72 | Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis. ( Chirehwa, M; Denti, P; Donald, PR; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; Mao, J; McIlleron, H; Norman, J; Schaaf, HS; van der Laan, LE; Wiesner, L; Winckler, JL, 2022) |
| "The final optimized model included the addition of variability in bioavailability and allometric scaling with body weight on disposition parameters." | 1.56 | Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens. ( Abulfathi, AA; Assawasuwannakit, P; Diacon, AH; Donald, PR; Reuter, H; Svensson, EM, 2020) |
| " Four grams of GSR-PAS twice daily but not 8 g once daily ensured concentrations exceeding the MIC (1 mg/liter) throughout the dosing interval; PAS intolerance was not related to maximum PAS concentrations over the doses studied and was not more frequent after once-daily dosing." | 1.42 | N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. ( de Kock, L; Diacon, AH; Donald, PR; Rosenkranz, B; Sy, SK; van der Merwe, L; Werely, CJ; Xia, H, 2015) |
| " The present paper draws on these recent studies, synthesizes pharmacokinetic results from different population groups, and draws comparisons with in vitro data and the results of earlier pharmacokinetic studies in order to discuss the most appropriate dosing regimen for PAS-GR." | 1.40 | Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis. ( Brochart, H; Diacon, AH; Donald, PR; Kibleur, Y; Schaaf, HS, 2014) |
| " This case study presents the development of a granular dosing spoon pediatric delivery system for para-aminosalicylic acid." | 1.39 | Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study. ( Becerra, MC; Brigden, G; Furin, J; Lessem, E, 2013) |
| "MDR-TB can be successfully treated during pregnancy by using a regimen including effective second-line anti-tuberculosis drugs." | 1.33 | [Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy]. ( Ano, H; Danno, K; Han, Y; Kawahara, K; Matsumoto, T; Nagai, T; Takashima, T; Tamura, Y; Tsuyuguchi, I; Yoshida, H, 2006) |
| "The study objective was to determine the minimum frequency of dosing for standard 4-g doses of p-aminosalicylic acid (PAS) granules." | 1.30 | Once-daily and twice-daily dosing of p-aminosalicylic acid granules. ( Berning, SE; Childs, JM; Huitt, GA; James, GT; Peloquin, CA; Singleton, MD, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (8.93) | 18.7374 |
| 1990's | 5 (8.93) | 18.2507 |
| 2000's | 12 (21.43) | 29.6817 |
| 2010's | 23 (41.07) | 24.3611 |
| 2020's | 11 (19.64) | 2.80 |
| Authors | Studies |
|---|---|
| Krátký, M | 3 |
| Vinšová, J | 4 |
| Buchta, V | 1 |
| Horvati, K | 2 |
| Bösze, S | 3 |
| Stolaříková, J | 4 |
| Vavříková, E | 1 |
| Polanc, S | 1 |
| Kočevar, M | 1 |
| Vávrová, K | 1 |
| Baranyai, Z | 1 |
| Szabó, I | 1 |
| Paraskevopoulos, G | 2 |
| Monteiro, S | 1 |
| Vosátka, R | 1 |
| Navrátilová, L | 1 |
| Trejtnar, F | 1 |
| Hegde, PV | 1 |
| Howe, MD | 1 |
| Zimmerman, MD | 1 |
| Boshoff, HIM | 1 |
| Sharma, S | 1 |
| Remache, B | 1 |
| Jia, Z | 1 |
| Pan, Y | 1 |
| Baughn, AD | 2 |
| Dartois, V | 1 |
| Aldrich, CC | 1 |
| Wu, X | 1 |
| Tan, G | 1 |
| Sha, W | 1 |
| Liu, H | 1 |
| Yang, J | 1 |
| Guo, Y | 1 |
| Shen, X | 1 |
| Wu, Z | 1 |
| Shen, H | 1 |
| Yu, F | 1 |
| van der Laan, LE | 1 |
| Garcia-Prats, AJ | 1 |
| Schaaf, HS | 2 |
| Chirehwa, M | 1 |
| Winckler, JL | 1 |
| Mao, J | 1 |
| Draper, HR | 1 |
| Wiesner, L | 1 |
| Norman, J | 1 |
| McIlleron, H | 1 |
| Donald, PR | 6 |
| Hesseling, AC | 1 |
| Denti, P | 1 |
| Li, Z | 1 |
| Liu, F | 1 |
| Chen, H | 1 |
| Han, Y | 2 |
| You, Y | 1 |
| Xie, Y | 1 |
| Zhao, Y | 1 |
| Tan, J | 1 |
| Guo, X | 1 |
| Cheng, Y | 1 |
| Wang, Y | 2 |
| Li, J | 1 |
| Cheng, M | 1 |
| Xia, S | 1 |
| Niu, X | 1 |
| Wei, L | 1 |
| Wang, W | 2 |
| Li, S | 1 |
| Ge, Q | 1 |
| Guo, H | 1 |
| Shang, Y | 1 |
| Ren, W | 1 |
| Xue, Z | 1 |
| Lu, J | 1 |
| Pang, Y | 1 |
| Pietersen, E | 1 |
| Anderson, K | 1 |
| Cox, H | 1 |
| Dheda, K | 1 |
| Bian, A | 1 |
| Shepherd, BE | 1 |
| Sterling, TR | 1 |
| Warren, RM | 1 |
| van der Heijden, YF | 1 |
| Dokladda, K | 1 |
| Billamas, P | 1 |
| Jaitrong, S | 1 |
| Suwanakitti, N | 1 |
| Phornsiricharoenphant, W | 1 |
| Viratyosin, W | 1 |
| Prammananan, T | 1 |
| Lan, Z | 1 |
| Ahmad, N | 1 |
| Baghaei, P | 1 |
| Barkane, L | 1 |
| Benedetti, A | 1 |
| Brode, SK | 1 |
| Brust, JCM | 1 |
| Campbell, JR | 1 |
| Chang, VWL | 1 |
| Falzon, D | 1 |
| Guglielmetti, L | 1 |
| Isaakidis, P | 2 |
| Kempker, RR | 1 |
| Kipiani, M | 1 |
| Kuksa, L | 1 |
| Lange, C | 1 |
| Laniado-Laborín, R | 1 |
| Nahid, P | 1 |
| Rodrigues, D | 1 |
| Singla, R | 1 |
| Udwadia, ZF | 1 |
| Menzies, D | 1 |
| Abulfathi, AA | 2 |
| Adams, K | 1 |
| Svensson, EM | 2 |
| Diacon, AH | 5 |
| Reuter, H | 2 |
| Assawasuwannakit, P | 1 |
| Jain, AK | 1 |
| Sharma, P | 1 |
| Caminero, JA | 1 |
| Piubello, A | 1 |
| Scardigli, A | 1 |
| Migliori, GB | 2 |
| Park, S | 2 |
| Jo, KW | 1 |
| Lee, SD | 1 |
| Kim, WS | 1 |
| Shim, TS | 1 |
| Fan, YM | 1 |
| Ding, SP | 1 |
| Bao, ZJ | 1 |
| Wu, LM | 1 |
| Zhen, LB | 1 |
| Xia, Q | 1 |
| Zhu, M | 1 |
| Ramachandran, G | 1 |
| Tola, HH | 1 |
| Holakouie-Naieni, K | 1 |
| Lejisa, T | 1 |
| Mansournia, MA | 1 |
| Yaseri, M | 1 |
| Tesfaye, E | 1 |
| Mola, M | 1 |
| Mpagama, SG | 1 |
| Heysell, SK | 1 |
| Ndusilo, ND | 1 |
| Kumburu, HH | 1 |
| Lekule, IA | 1 |
| Kisonga, RM | 1 |
| Gratz, J | 1 |
| Boeree, MJ | 1 |
| Houpt, ER | 1 |
| Kibiki, GS | 1 |
| Furin, J | 1 |
| Brigden, G | 1 |
| Lessem, E | 1 |
| Becerra, MC | 1 |
| Andries, A | 1 |
| Das, M | 1 |
| Khan, S | 1 |
| Paryani, R | 1 |
| Desai, C | 1 |
| Dalal, A | 1 |
| Mansoor, H | 1 |
| Verma, R | 1 |
| Fernandes, D | 1 |
| Sotgiu, G | 1 |
| Saranchuk, P | 1 |
| Kibleur, Y | 1 |
| Brochart, H | 1 |
| de Kock, L | 2 |
| Sy, SK | 2 |
| Rosenkranz, B | 2 |
| Prescott, K | 1 |
| Hernandez, KR | 1 |
| Yu, M | 1 |
| Derendorf, H | 1 |
| Werely, CJ | 1 |
| Xia, H | 1 |
| van der Merwe, L | 1 |
| Minato, Y | 1 |
| Thiede, JM | 1 |
| Kordus, SL | 1 |
| McKlveen, EJ | 1 |
| Turman, BJ | 1 |
| Nguyen, L | 1 |
| Zhao, W | 1 |
| Zheng, M | 1 |
| Wang, B | 1 |
| Mu, X | 1 |
| Li, P | 1 |
| Fu, L | 1 |
| Liu, S | 1 |
| Guo, Z | 1 |
| McNaughton, A | 1 |
| Blackmore, T | 1 |
| McNaughton, H | 1 |
| Lai, CC | 1 |
| Tan, CK | 1 |
| Huang, YT | 1 |
| Liao, CH | 1 |
| Hsueh, PR | 1 |
| Vesenbeckh, SM | 1 |
| Becker, J | 1 |
| Huhnt, C | 1 |
| Karras, B | 1 |
| Bauer, TT | 1 |
| Mauch, H | 1 |
| Rüssmann, H | 1 |
| Schönfeld, N | 1 |
| Yano, S | 1 |
| Kobayashi, K | 1 |
| Ikeda, T | 1 |
| Kim, JH | 1 |
| Jang, SH | 1 |
| Kim, DH | 1 |
| Kim, DG | 1 |
| Jung, KS | 1 |
| Wilson, JW | 1 |
| Kelkar, P | 1 |
| Frigas, E | 1 |
| BRUN, J | 1 |
| VIALLIER, J | 1 |
| DUMONT, R | 1 |
| SHIGEMATSU, T | 1 |
| CORPE, RF | 1 |
| BLALOCK, FA | 1 |
| GROSS, JH | 1 |
| GOLDHAMMER, EJ | 1 |
| SCHLESS, JM | 1 |
| ALLISON, RF | 1 |
| INGLIS, RM | 1 |
| WHITE, EF | 1 |
| TOPPERMAN, S | 1 |
| Novozhylova, IO | 1 |
| Park, SK | 1 |
| Lee, WC | 1 |
| Lee, DH | 1 |
| Mitnick, CD | 1 |
| Han, L | 1 |
| Seung, KJ | 1 |
| Zheng, XM | 1 |
| Li, SM | 1 |
| Xing, BC | 1 |
| Rengarajan, J | 1 |
| Sassetti, CM | 1 |
| Naroditskaya, V | 1 |
| Sloutsky, A | 1 |
| Bloom, BR | 1 |
| Rubin, EJ | 1 |
| Takashima, T | 1 |
| Danno, K | 1 |
| Tamura, Y | 1 |
| Nagai, T | 1 |
| Matsumoto, T | 1 |
| Ano, H | 1 |
| Yoshida, H | 1 |
| Kawahara, K | 1 |
| Tsuyuguchi, I | 1 |
| Steiner, M | 1 |
| Cosio, A | 1 |
| Dhingra, VK | 1 |
| Rajpal, S | 1 |
| Mittal, A | 1 |
| Hanif, M | 1 |
| Kruijshaar, ME | 1 |
| Watson, JM | 1 |
| Drobniewski, F | 1 |
| Anderson, C | 1 |
| Brown, TJ | 1 |
| Magee, JG | 1 |
| Smith, EG | 1 |
| Story, A | 1 |
| Abubakar, I | 1 |
| Ruggiero, SL | 1 |
| Hilton, E | 1 |
| Braun, TW | 1 |
| Aoyagi, T | 1 |
| Soumakis, SA | 1 |
| Berg, D | 1 |
| Harris, HW | 1 |
| Peloquin, CA | 2 |
| Berning, SE | 1 |
| Huitt, GA | 1 |
| Childs, JM | 1 |
| Singleton, MD | 1 |
| James, GT | 1 |
| Ye, Z | 1 |
| Pei, X | 1 |
| Yang, Y | 1 |
| Fodor, T | 1 |
| Pataki, G | 1 |
| Schrettner, M | 1 |
| Mizutani, H | 1 |
| Horiba, M | 1 |
| Shindoh, J | 1 |
| Kimura, T | 1 |
| Son, M | 1 |
| Wakahara, K | 1 |
| Reid, J | 1 |
| Marciniuk, D | 1 |
| Hoeppner, V | 1 |
| Petryszyn, K | 1 |
| LeLacheur, S | 1 |
7 reviews available for aminosalicylic acid and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Canada; Clofazimine; Diarylquinolines; Drug-Relat | 2020 |
The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.
Topics: Aminosalicylic Acid; Antitubercular Agents; Delayed-Action Preparations; Humans; Microbial Sensitivi | 2020 |
Pharmacokinetics of Second-Line Anti-Tubercular Drugs.
Topics: Aminoglycosides; Aminosalicylic Acid; Antitubercular Agents; Child; Cycloserine; Ethionamide; Fluoro | 2019 |
Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis.
Topics: Aminosalicylic Acid; Antitubercular Agents; Cross-Sectional Studies; Drug-Related Side Effects and A | 2019 |
Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.
Topics: Aminosalicylic Acid; Antitubercular Agents; Folic Acid; Microbial Sensitivity Tests; Mycobacterium t | 2015 |
Antibiotic resistance mechanisms in M. tuberculosis: an update.
Topics: Aminosalicylic Acid; Antibiotics, Antitubercular; Antitubercular Agents; Drug Resistance, Multiple, | 2016 |
[Chemotherapy for tuberculosis; yesterday, today, and tomorrow--basic and clinical studies].
Topics: Aminosalicylic Acid; Antitubercular Agents; Controlled Clinical Trials as Topic; Drug Delivery Syste | 1998 |
3 trials available for aminosalicylic acid and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Adult; Alkynes; Aminosalicylic Acid; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cr | 2014 |
[Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aminosalicylic Acid; Aminosalicylic Acids; Clinical | 2004 |
[Analysis of causes of drug resistance and therapeutic effects on 27 multi-drug resistant pulmonary tuberculosis patients].
Topics: Adult; Aminosalicylic Acid; Anti-Infective Agents; Antitubercular Agents; Drug Resistance, Multiple; | 1997 |
46 other studies available for aminosalicylic acid and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
New amino acid esters of salicylanilides active against MDR-TB and other microbes.
Topics: Amino Acids; Anti-Bacterial Agents; Antifungal Agents; Bacteria; Dose-Response Relationship, Drug; D | 2010 |
New fluorine-containing hydrazones active against MDR-tuberculosis.
Topics: Animals; Antitubercular Agents; Cell Line; Fluorine; Humans; Hydrazones; Microbial Sensitivity Tests | 2011 |
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacteria; Bacterial Infections; Benzoates; Fungi; Humans; | 2015 |
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
Topics: Antitubercular Agents; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Microb | 2017 |
Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
Topics: Aminosalicylic Acid; Animals; Antitubercular Agents; Biological Availability; Mice; Prodrugs; Tuberc | 2022 |
Use of Whole-Genome Sequencing to Predict
Topics: Amikacin; Aminosalicylic Acid; Antitubercular Agents; China; Cycloserine; Drug Resistance; Ethambuto | 2022 |
Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Child; Drug Administration Schedule; HIV Infectio | 2022 |
A five-year review of prevalence and treatment outcomes of pre-extensively drug-resistant plus additional drug-resistant tuberculosis in the Henan Provincial Tuberculosis Clinical Medicine Research Centre.
Topics: Aminosalicylic Acid; Antitubercular Agents; Clinical Medicine; COVID-19; Extensively Drug-Resistant | 2022 |
Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations.
Topics: Aminosalicylic Acid; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivit | 2022 |
Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa.
Topics: Adult; Amikacin; Aminosalicylic Acid; Antitubercular Agents; Ethionamide; Female; HIV Infections; Ho | 2023 |
Whole genome sequencing reveals candidate genes involving in PAS resistance in M. Tuberculosis isolated from patients in Thailand.
Topics: Aminosalicylic Acid; Antitubercular Agents; DNA, Intergenic; Drug Resistance, Bacterial; Folic Acid; | 2023 |
Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens.
Topics: Aminosalicylic Acid; Antitubercular Agents; Drug Administration Schedule; Humans; Microbial Sensitiv | 2020 |
Ethionamide induced blue vision (cyanopsia): Case report.
Topics: Aminosalicylic Acid; Antitubercular Agents; Color Vision Defects; Cycloserine; Ethionamide; Female; | 2020 |
Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.
Topics: Aminosalicylic Acid; Antitubercular Agents; Carbapenems; Clofazimine; Communicable Disease Control; | 2017 |
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Topics: Adult; Age Distribution; Aged; Alcohol Drinking; Aminosalicylic Acid; Antitubercular Agents; Cohort | 2017 |
Prognostic factors for treatment success in patients with multidrug-resistant tuberculosis in China.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acid; Antitubercular Agents; Child; China; Cycloserine; Drug | 2018 |
Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.
Topics: Adult; Aminoglycosides; Aminosalicylic Acid; Antitubercular Agents; Comorbidity; Drug Resistance, Mu | 2013 |
Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study.
Topics: Administration, Oral; Age Factors; Aminosalicylic Acid; Antitubercular Agents; Chemistry, Pharmaceut | 2013 |
High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India.
Topics: Adult; Aminosalicylic Acid; Cohort Studies; Coinfection; Ethionamide; Female; HIV Infections; Humans | 2013 |
Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Aminosalicylic Acid; Chemistry, Pharmaceutical; Child; Child, Preschool; Clinical | 2014 |
N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.
Topics: Acetyltransferases; Adolescent; Adult; Alleles; Aminosalicylic Acid; Antitubercular Agents; Arylamin | 2015 |
Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
Topics: Aminosalicylic Acid; Animals; Antitubercular Agents; Capreomycin; Drug Combinations; Drug Interactio | 2016 |
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Cl | 2016 |
Fluoroquinolone-resistant tuberculosis at a medical centre in Taiwan, 2005-10.
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antitubercular Agents; Drug Resistance, Bacteri | 2011 |
Successful oral desensitization to i.v. para-aminosalicylic acid (PAS) using encapsulated PAS dry substance.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Capsules; Desensitization, Immunologic; Dose-Resp | 2012 |
Multidrug-resistant tuberculosis that required 2 years for diagnosis.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Diagnosis, Differential; Humans; Male; Ofloxacin; | 2012 |
A case of DRESS syndrome induced by the antituberculosis drugs, prothionamide, and para-aminosalycilic acid.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Drug Eruptions; Eosinophilia; Humans; Male; Proth | 2013 |
Para-aminosalicylic acid (PAS) desensitization review in a case of multidrug-resistant pulmonary tuberculosis.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Desensitization, Immunologic; Female; Humans; Tub | 2003 |
[Evolution of streptomycin-resistant tuberculosis].
Topics: Aminosalicylic Acid; Biological Evolution; Streptomycin; Tuberculosis; Tuberculosis, Multidrug-Resis | 1952 |
[THE PROBLEM OF INFECTION WITH DRUG-RESISTANT MICROORGANISMS-TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Isoniazid; J | 1963 |
RE-TREATMENT OF DRUG-RESISTANT PULMONARY TUBERCULOSIS AT BATTEY STATE HOSPITAL.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial; | 1964 |
THE USE OF ETHIONAMIDE IN COMBINED DRUG REGIMENS IN THE RE-TREATMENT OF ISONIAZID-RESISTANT PULMONARY TUBERCULOSIS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resi | 1965 |
[M. tuberculosis drug resistance and occurrence in patients with pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Incidence; Kanamycin | 2003 |
Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antitubercular Agents; Cohort Studi | 2004 |
The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria.
Topics: Aminosalicylic Acid; Drug Resistance, Bacterial; Drug Resistance, Multiple; Folic Acid; Folic Acid A | 2004 |
[Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy].
Topics: Adult; Aminosalicylic Acid; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Cy | 2006 |
Primary tuberculosis in children. 1. Incidence of primary drug-resistant disease in 332 children observed between the years 1961 and 1964 at the Kings County Medical Center of Brooklyn.
Topics: Aminosalicylic Acid; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Bacterial; Fem | 1966 |
Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic.
Topics: Adolescent; Adult; Aminoglycosides; Aminosalicylic Acid; Antitubercular Agents; Child; Cycloserine; | 2008 |
Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Disease Susceptibility; Epidemiologic Methods; Et | 2008 |
Trismus and preauricular swelling in a 20-year-old black woman.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Capreomycin; Diagnosis, Differential; Edema; Etha | 1996 |
Hypothyroidism in a patient receiving treatment for multidrug-resistant tuberculosis.
Topics: Aminosalicylic Acid; Antitubercular Agents; Humans; Hypothyroidism; Male; Middle Aged; Tuberculosis, | 1998 |
Once-daily and twice-daily dosing of p-aminosalicylic acid granules.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antitubercular Agents; Chromatograp | 1999 |
PAS infusion in treatment of multidrug-resistant tuberculosis.
Topics: Aminosalicylic Acid; Antitubercular Agents; Drug Therapy, Combination; Evaluation Studies as Topic; | 2000 |
[Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism].
Topics: Adult; Aged; Aminosalicylic Acid; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; | 2001 |
Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Female; Gastrostomy; Humans; Jejunostomy; Levoflo | 2002 |
MDR-TB: a challenge for the 21st century.
Topics: Aminosalicylic Acid; Drug Resistance, Bacterial; Drug Therapy, Combination; Forecasting; Humans; Iso | 2002 |